

In the Sequence Listing:

Please insert the attached substitute paper copy of the Sequence Listing as new pages 1-9 in the above-captioned application.

Amendments

In the claims:

Please amend rewritten claim 1 as follows:

1. (Version A). A peptide dimer that inhibits cytotoxicity and consists of 12 to 60 amino acids, and has the one of the following structures:

R E aa<sup>77</sup> L R aa<sup>80-83</sup> Y (I) (SEQ ID NO:38) or

Y aa<sup>83-80</sup> R L aa<sup>77</sup> E R (II) (SEQ ID NO:39), and

N-terminal acylated and/or C-terminal amidated or esterified forms;

Please amend claim 15 as follows:

15. (Amended) The [compound] peptide of claim [1] 27 wherein [each of  $\alpha$  and  $\beta$  independently] comprises RIALRYYRLAIR (SEQ ID NO:40), YRLAIRRIALRY (SEQ ID NO:36), RIALRYRILLRY (SEQ ID NO:41) or YRLLIRYRLAIR (SEQ ID NO:42).

Please amend claim 16 as follows:

16. (Amended) The [compound] peptide of claim [1] 27 which is YRLAIRLNERNENRLIALRY (SEQ ID NO:26) or YRLAIRLNERYRLAIRLNER (SEQ ID NO:31).

Please amend claim 17 as follows:

17. (Amended) The [compound] peptide of claim [1] 27 which is YRLAIRRIALRY (SEQ ID NO:36).